Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 1.00 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.67 |
| ▸ | F3 | P13726 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | TYR | P14679 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126013 | 1.00 | HSD11B1 (1.00) | HSD11B1TNFRSF1AF3CYP2D6CYP2C9 | |
| SCHEMBL28357102 | 0.92 | HSD11B1 (0.84) | HSD11B1TNFRSF1AF3CYP2D6CYP2C9 | |
| SCHEMBL10467662 | 0.90 | HSD11B1 (0.81) | HSD11B1TNFRSF1AF3CYP2D6CYP2C9 | |
| SCHEMBL10467661 | 0.90 | HSD11B1 (0.81) | HSD11B1TNFRSF1AF3CYP2D6CYP2C9 | |
| SCHEMBL29428461 | 0.87 | HSD11B1 (0.77) | HSD11B1TNFRSF1AF3CYP2D6CYP2C9 | |
| SCHEMBL22596716 | 0.86 | HSD11B1 (0.75) | HSD11B1TNFRSF1ALMNAALDH1A1MAPT | |
| SCHEMBL23136570 | 0.86 | HSD11B1 (0.74) | HSD11B1TNFRSF1AF3CYP2D6CYP2C9 | |
| SCHEMBL20586532 | 0.86 | HSD11B1 (0.74) | HSD11B1TNFRSF1AF3CYP2D6CYP2C9 | |
| SCHEMBL81378 | 0.84 | HSD11B1 (0.72) | HSD11B1TNFRSF1ACYP2C9TYRLMNA | |
| SCHEMBL3476254 | 0.84 | HSD11B1 (0.72) | HSD11B1TNFRSF1ACYP2C9TYRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | claimed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-4347232-A | Preparation of hydrogen peroxide from its elements | FMC CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-11-28 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-06 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| US-20230378534-A1 | CYCLIC SULFONE ADDITIVES FOR LITHIUM ION BATTERIES | NOHMs Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230378534-A1 | CYCLIC SULFONE ADDITIVES FOR LITHIUM ION BATTERIES | NOHMs Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| WO-2022140561-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-06-30 | — | — | WO | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| EP-0758327-B1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| US-RE29358-E | ANTI-MALARIA AND ANTI-TUBERCULOSIS AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | HSD11B1 1114/4885TNFRSF1A 3175/4885F3 3275/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | HSD11B1 1610/4885TNFRSF1A 2552/4885F3 4781/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | HSD11B1 2836/4885TNFRSF1A 2086/4885F3 4264/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | HSD11B1 3453/4885TNFRSF1A 1039/4885F3 3771/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | HSD11B1 1894/4885TNFRSF1A 3270/4885F3 3876/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | HSD11B1 1894/4885TNFRSF1A 3270/4885F3 3876/4885 |
| US-20230378534-A1 | CYCLIC SULFONE ADDITIVES FOR LITHIUM ION BATTERIES | NCS1, TST, NDUFS8 | HSD11B1 1926/4885TNFRSF1A 4872/4885F3 4734/4885 |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | MAVS, IDO2, IDO1 | HSD11B1 1837/4885TNFRSF1A 3746/4885F3 1944/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | HSD11B1 2836/4885TNFRSF1A 2086/4885F3 4264/4885 |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | MAVS, IDO2, IDO1 | HSD11B1 1570/4885TNFRSF1A 4295/4885F3 1370/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | HSD11B1 1013/4885TNFRSF1A 2777/4885F3 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.